Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Shares Issued (2016 - 2025)

Ptc Therapeutics (PTCT) has 12 years of Shares Issued data on record, last reported at $59.4 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 123.33% year-over-year to $59.4 million; the TTM value through Dec 2025 reached $93.1 million, up 225.93%, while the annual FY2025 figure was $93.1 million, 225.93% up from the prior year.
  • Shares Issued reached $59.4 million in Q4 2025 per PTCT's latest filing, up from $30.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $59.4 million in Q4 2025 and bottomed at -$12.9 million in Q2 2025.
  • Average Shares Issued over 5 years is $9.4 million, with a median of $2.9 million recorded in 2022.
  • Peak YoY movement for Shares Issued: skyrocketed 9785.5% in 2024, then tumbled 22573.68% in 2025.
  • A 5-year view of Shares Issued shows it stood at $1.2 million in 2021, then surged by 181.16% to $3.3 million in 2022, then tumbled by 91.95% to $269000.0 in 2023, then surged by 9785.5% to $26.6 million in 2024, then surged by 123.33% to $59.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $59.4 million in Q4 2025, $30.9 million in Q3 2025, and -$12.9 million in Q2 2025.